Who should, and should not get the Covid

相关推荐

• 针对新冠病毒突变，辉瑞/BioNTech疫苗展现保护效力

  ▎药明康德内容团队编辑 去年12月,英国的研究人员发现一种具有高度传染性的新冠病毒突变体正在英国传播.此后在南非也发现一种传播迅速的新病毒突变体.这些传播迅速的突变体很快得到全球的关注,不仅是因为它们 ...

• Here's Why Some Health Care Workers Don't Want The COVID

  America's health care workers have lived through unspeakable trauma over the last year, putting thei ...

• COVID Outbreak Confirmed At Nursing Home Despite Staff, Patients Being Vaccinated

  https://www.traderszone.net/covid-outbreak-confirmed-nursing-home-despite-staff-patients-being-vacci ...

• Pfizer’s covid-19 vaccine is highly effective, but don’t expect to get it soon

  A promising vaccine against covid-19 has proved 90% effective, protecting most people who get it, ac ...

• 英国批准辉瑞疫苗，最快下周开始接种

  当地时间周三,英国药品和保健产品监管署(Medicines and Healthcare products Regulatory Agency, MHRA)批准了德国生物新技术公司(BioNTech) ...

• 被怀疑了30年mRNA疫苗: 疫情该打不该打

  [留美学子]第2030期 国际视角的精选文摘 教育·历史·人物·旅游·读书·财经 仰望星空,脚踏实地 导语 作者雷春老师一如既往的严谨和翔实的文字,再次为读者呈现了疫情里大家谈论的疫苗! 本期分享内容 ...

• 新冠疫苗重大突破！辉瑞刚刚发布新冠疫苗三期临床试验中期数据，宣布其疫苗预防新冠肺炎的有效性超过90%...

  如果辉瑞和BioNTech刚刚发布的未经同行评审的三期临床试验数据真实可靠的话,人类与新冠肺炎之间的全球性战争终于迎来关键性时间节点. 辉瑞及其合作伙伴BioNTech数个小时前在官网发布消息称[1, ...

• 90%有效率！mRNA新冠疫苗三期临床数据积极，可有效预防COVID-19

  mRNA新冠候选疫苗BNT162b2针对COVID-19的功效的评估结果于11月9日公布.三期临床试验第一阶段中期疗效分析结果显示,该疫苗在预防健康受试者感染新冠病毒的有效率超过90%.这一数据已经远 ...

• A Simple Question Going Unanswered About COVID Vaccines

  April 29, 2021  NEWS0 Comments Authored by Mark Glennon via Wirepoints.org, "The emerging data ...

• 关于线材（四）

  pocket tips 小知识 羊毛 wool Probably the best known knitting material,"wool"can be obtained fr ...

• Who is Sean Brooks? Man with ‘Oxford PHD’ goes viral

  Ellissa BainAnother video from a school board meeting has gone viral with outlandish and unproven cl ...

• "Superforecasters" Now See 90% Odds 200 Million Americans Will Be Vaccinated By October

  "Superforecasters" Now See 90% Odds 200 Million Americans Will Be Vaccinated By October Op ...